CNA-3103 is under clinical development by Carina Biotech and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CNA-3103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CNA-3103 overview
CNA-3103 is under development for the treatment of ovarian cancer, metastatic colorectal cancer and other solid tumor. The therapeutic candidates comprise autologous T cells genetically engineered to express chimeric antigen receptor (CAR). It acts by targeting LGR5 (leucine-rich repeat-containing G protein-coupled receptor 5). It is administered through intravenous route. It is being developed based on multifunctional chemokine receptor platform.
It was also under development for the treatment of hematological tumor.
Carina Biotech overview
Carina Biotech is a pre-clinical immunotherapy company that carries out the research and development of chimeric antigen receptor T cell (CAR-T) and other adoptive cell therapies. The company’s pipeline products include LGR5 stem cell antigen, GPC-1, ADAM-10, i-body enabled, bi-specific CAR-Ts and nfp2X7. It conducts clinical trials in phases to develop therapies for the treatment of solid cancers such as hematological, ovarian, prostrate, colorectal cancer, breast cancer, neuroblastoma and other solid tumors. Carina Biotech through its proprietary multifunctional chemokine receptor platform develops technologies to improves access to and infiltration of solid cancers and also enhances CAR-T cell manufacturing. The company works in collaboration with Cooperative Research Centre, Women’s & Children’s Hospital Foundation, MTPConnect, TechInSA and Seattle Children’s Research Institute. Carina Biotech is headquartered in Mawson Lakes, South Australia, Australia.
For a complete picture of CNA-3103’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
